Free Trial

Danaher (DHR: A3 pos / A-): Preview

HEALTHCARE
  • Issuance might be a risk after earnings.
  • Danaher haven’t issued since Dec ’21 when they called the 2.5% July 25.
  • In hindsight, that was probably an opportunistic attempt to lock-in low interest rates before the inflation sell-off.
  • The company has $1.2b coming due in the next 4-13 months.
  • Credit spreads are currently low – not as low as April/May – but low enough to attract the attention of an active treasury department. (We are in the 6th percentile over 10yrs on BofA BBB Index)
  • Danaher guided for low single digit declines in core revenue year-over-year.
  • Moody’s placed them on Positive in June so clearly the revenue decline is not a problem as leverage remains low. Moody’s expect it to be <3x absent large acquisitions.
  • Diagnostic business expected to decline -15% qoq
  • Biotechnology should offset this to some degree with 7% increase
  • Total Debt/EBITDA expected to rise by 0.5x but within Moody’s ranges

To read the full story

Close

Why MNI

MNI is the leading provider

of intelligence and analysis on the Global Fixed Income, Foreign Exchange and Energy markets. We use an innovative combination of real-time analysis, deep fundamental research and journalism to provide unique and actionable insights for traders and investors. Our "All signal, no noise" approach drives an intelligence service that is succinct and timely, which is highly regarded by our time constrained client base.

Our Head Office is in London with offices in Chicago, Washington and Beijing, as well as an on the ground presence in other major financial centres across the world.